rare diseasesSynaptixBio Ltd gets FDA ODD for leukodyst...Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy. more ➔
cancerPierre Fabre SAS in US$31m licence deal wi...Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc. more ➔
OphtalmologyPulseSight to disrupt AMD spacePulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, … more ➔
vaccineSwiss vaccine developer Limma Tech get CAR...Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). more ➔
financingCurve Therapeutics raises £40.5m in Serie...Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides. more ➔
financingPacifico Biolabs raises US$3.3m in pre-see...German foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood. more ➔
gene therapyGene therapy supplier MIP Discovery closes...MIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy. more ➔
cancerVidac Pharma Holding plc reports preclinic...London-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer. more ➔
